Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Central Sleep Apnoea in Patients With Heart Failure With Nasal High Flow Therapy (nHFT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Moderate to severe CSA/CSR (AHI\>15), in which CSA is defined when at least 50% of the apnoeas are central apnoeas~2. Heart failure with reduced ejection fraction, defined as a LVEF \< 45% of predicted~Exclusion Criteria:~1. Other diseases affecting respiration during sleep (COPD GOLD 3 or 4, neuromuscular disorders, thorax cage deformities)~2. At the moment of the inclusion, the patient does not have a therapy to treat the CSA, such as continuous positive airway pressure (CPAP), oxygen, bilevel intermittent positive airway pressure (BiPAP) or acetazolamide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasal high flow oxygen therapy (Type: EXPERIMENTAL): The patient is hospitalized for one night.~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:~* Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)~* High flow rate: 40-50 L/min without additional oxygen~* Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)~* High flow rate: 40-50 L/min with FiO2 of 28%

Based on this trial design, predict the completion outcome and termination type (if applicable).